BioCision ThawSTAR Wins Top Honor for Innovation and Design
News Aug 27, 2015
BioCision, LLC has announced that they received Instrument Business Outlook’s (IBO) Gold Award for its ThawSTAR™ automated cell thawing system.
Candidates are chosen from new products that IBO monitors through trade shows, trade publications, press releases and the Internet. Award winners are selected solely based on their industrial design; criteria include innovation, aesthetics, functionality and utility for products that have begun shipping between August 2014 and July 2015. The winners demonstrate how industrial design can improve a product’s functionality and the end-user’s experience.
According to IBO, the ThawSTAR cell thawing system was chosen for its novel approach to lab equipment design represented in its compact size, touchscreen-free intuitive interface and white finish that communicates simplicity. “The ThawSTAR system won IBO’s Gold Award in the lab equipment industrial design category because not only does it bring a modern and sleek appearance to lab equipment, but also represents a breakthrough technology,” said Brian Schryver, Vice President, Product Development.
The ThawSTAR system automatically thaws frozen 1.8 to 2.0 mL cryogenic vials containing cells or other biospecimens, replacing manual methods such as thawing vials in warm water baths. Measuring only 11.0 x 14.5 cm and weighing 1.2 kg with a power supply, the ThawSTAR system can be readily placed into a laminar flow hood where the rest of the cell handling workflow is performed.
“Our goal with ThawSTAR was to provide a novel product that standardizes an important step in (stem) cell handling in the lab and clinic. The intuitive, user-friendly interface has been extremely well received by our customers and is a testament to the vision of bringing easy-to-operate translational (research to clinic) devices to market,” said Dr. Rolf O. Ehrhardt, BioCision Chief Executive Officer. “When science, engineering and design come together, everyone wins including clinicians, patients, researchers, and laboratory personnel.”